Head-to-head · WeighScore
Invigor Medical vs Tuyo Health
By GLP-1 ScorecardUpdated
Score comparison
Invigor Medical has the higher recorded score — 86.1/100 to 72.5/100.
Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Now Try Invigor, this platform advertises class-based GLP-1 plans; confirm your medicine and supply before accepting its starting price.
Before you choose
Before comparing the headline prices, the Invigor Medical review and the Tuyo Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Invigor Medical vs UR Meds and Ondra Health vs Tuyo Health compare each of them with another graded program, and the list of alternatives to Invigor Medical ranks the programs closest to Invigor Medical on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Strut Health review covers one graded close to these two, at 79.4/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Invigor Medical | Tuyo Health |
|---|---|---|
| WeighScore | 86.1/100 | 72.5/100 |
| Grade | B | C |
| Site position | #9 | #88 |
| Semaglutide | Medication-specific quote unconfirmed; public GLP-1 treatment starts at $225. | GLP-1 plans from $155/mo; confirm the selected drug and renewal |
| Tirzepatide | Medication-specific quote unconfirmed; public GLP-1 + GIP treatment starts at $350/month. | Drug-specific price not disclosed |
| Coverage | U.S. only; confirm medication-specific state availability | Confirm treatment-specific availability |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Consultation, medication and supplies advertised together
- Ordinary and microdose treatment listings are separately presented
- Clinical policy describes virtual consultation and relevant testing when needed
What to consider
- Current medication-specific dose and supply quote is unconfirmed
- Cancel new orders before the prescription enters the practitioner's queue
- Subscriptions need seven days’ notice before renewal processing; charges may occur early
- No universal GLP-1 lab panel, frequency or separate testing price published
FDAWarning letter issued to Tuyo Health, Inc. dba Tuyo Health in September 2025. See the FDA warning-letter database.
Strengths
- Public terms explain the renewal cancellation deadline and participating-pharmacy billing
What to consider
- Public starting figure does not establish a medication-specific price or refill schedule
- Assigned pharmacy and coverage depend on the selected plan
- FDA issued Tuyo Health, Inc. dba Tuyo Health a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.